The 41st Annual Critical Issues in Tumor Microenvironment course explores how the surroundings of a tumor influence growth, metastasis, and response to treatment. Directed by Rakesh K. Jain, the four-day program brings together research on blood vessels, fibroblasts, extracellular matrix, immune cells, and cancer metabolism. Sessions extend into cancer neuroscience, the microbiome, circadian biology, and single-cell and spatial genomics, with examples from adult and pediatric tumors. For oncology clinicians and researchers, the emphasis is on evaluating emerging findings and their translational implications. The full agenda below preserves the presentations, discussion periods, speakers, and sessions identified as pre-recorded.
Original course: September 14–17, 2026, offered live online by Massachusetts General Hospital through Harvard Medical School Continuing Education. English-language program directed by Rakesh K. Jain, PhD. The original provider offered registered participants 30 days of recorded viewing; that provider access is not part of this store purchase.
Package scope: The agenda describes the original educational program, including breaks and discussion periods; it does not establish the exact inventory or completeness of the supplied files. Provider registration, live attendance, publisher-platform access, accounts, memberships, apps, and publisher-hosted extras are not included.
Learning Objectives
Upon completion of this course, participants should be able to:
- Identify pharmacological approaches to normalize the tumor microenvironment, including tumor-associated blood vessels, fibroblasts, and the extracellular matrix.
- Evaluate molecularly targeted agents approved or currently in clinical development in combination with immunotherapies for cancer treatment and incorporate them into practice.
- Identify emerging determinants of immunotherapy outcomes, including blood vessels, fibroblasts, extracellular matrix, neuronal-tumor interactions, circadian cycle, microbiome, and discuss potential approaches to harness them.
- Compare correlative studies of biomarkers and their response and resistance to immunotherapies in cancer patients.
- Evaluate state-of-the-art genetic and imaging techniques and their applications in pre-clinical and clinical studies.
- Assess relevant, state-of-the-art, or translational pre-clinical models of anti-cancer therapies for adult and pediatric malignancies.
- Recognize the steps and determinants of the metastatic process of cancer.
- Identify the applications of AI in cancer care and research.
Topics and Program
Day 1: Monday, September 14, 2026
| Time | Content | Speaker |
| 10:00 – 10:10 am | Opening Remarks | Rakesh Jain |
| 10:10 – 11:20 am | Tumor Microenvironment I: Angiogenesis and Vascular Function | Rakesh Jain |
| 11:20 – 11:35 am | Q&A | Rakesh Jain; Dai Fukumura |
| 11:35 – 11:50 am | Break | |
| 11:50 am – 1:10 pm | Tumor Microenvironment II: Vascular Normalization and Immunotherapy | Rakesh Jain |
| 1:10 – 1:25 pm | Q&A | Rakesh Jain; Dai Fukumura |
| 1:25 – 2:25 pm | Lunch Break | |
| 2:25 – 3:45 pm | Tumor Microenvironment III: Extracellular Matrix, Lymphatics and Metastasis | Rakesh Jain |
| 3:45 – 4:00 pm | Q&A | Rakesh Jain; Dai Fukumura |
| 4:00 – 4:30 pm | Break | |
| 4:30 – 5:35 pm | Cancer Immunology and Immunotherapy Overview | Arlene Sharpe |
| 5:35 – 5:50 pm | Q&A | Arlene Sharpe; Zohreh Amoozgar |
Day 2: Tuesday, September 15, 2026
| Time | Content | Speaker |
| 10:00 – 11:05 am | Skull Bone Marrow as a Site for Immuno- Surveillance of Healthy Brain and Brain Tumors | Jonathan Kipnis |
| 11:05 – 11:20 am | Q&A | Marc Charbati |
| 11:20 – 11:50 am | Break | |
| 11:50 am – 12:55 pm | Neuron-Cancer Interactions in the TME *pre-recorded | Michelle Monje |
| 12:55 – 1:10 pm | Q&A | Anna Geraghty |
| 1:10 – 2:10 pm | Break | |
| 2:10 – 3:15 pm | Determinants of How Tumors Use Metabolism to Support Growth | Matthew Vander Heiden |
| 3:15 – 3:30 pm | Q&A | Sonu Subudhi |
| 3:30 – 4:00 pm | Break | |
| 4:00 – 5:05 pm | Emerging Strategies to Improve CAR-T cell Therapy for Glibolastoma and other Solid Tumors | Hideho Okada |
| 5:05 – 5:20 pm | Q&A | Sumedha Pareek |
Day 3: Wednesday, September 16, 2026
| Time | Content | Speaker |
| 10:00 – 11:05 am | AI in Basic and Clinical Oncology | Eliezer Van Allen |
| 11:05 – 11:20 am | Q&A | Sonu Subudhi |
| 11:20 – 11:50 am | Break | |
| 11:50 am – 12:55 pm | Dissecting the Ecosystem of Gliomas by Single-Cell and Spatial Genomics | Mario Suva |
| 12:55 – 1:10 pm | Q&A | Daniel Radin |
| 1:10 – 2:30 pm | Lunch Break | |
| 2:30 – 3:30 pm | Mechanisms of the Gut Microbiome from Biomarker to Immunotherapy Adjuvant | Bertrand Routy |
| 3:30 – 3:45 pm | Q&A | Benjamin Wolf |
| 3:45 – 4:00 pm | Break | |
| 4:00 – 5:05 pm | RREBELLIOUS INTERFERENCE: Challenging old paradigms and discovering new strategies for targeting pediatric brain tumors | Robert Wechsler-Reya |
| 5:05 – 5:20 pm | Q&A | Taylor Uccello |
Day 4: Thursday, September 17, 2026
| Time | Content | Speaker |
| 10:00 – 11:05 am | Fibroblast Heterogeneity in Solid Tumors: Implications for Pancreatic Cancer | David Tuveson |
| 11:05 – 11:20 am | Q&A | Heena Kumra |
| 11:20 – 11:50 am | Break | |
| 11:50 am – 12:55 pm | Metastasis Ecosystems | Joan Massague |
| 12:55 – 1:10 pm | Q&A | Lei Xu |
| 1:10 – 2:10 pm | Break | |
| 2:10 – 3:15 pm | Identifying Immune Vulnerabilities in Solid Tumors *pre-recorded | Lisa Coussens |
| 3:15 – 3:30 pm | Q&A | Sumedha Pareek |
| 3:30 – 4:00 pm | Break | |
| 4:00 – 5:05 pm | Circadian Clock and Metabolic Vulnerabilities of Cancer | Chi Dang |
| 5:05 – 5:20 pm | Q&A | Melin Khandekar |
| 5:20 – 5:30 pm | Summary and Closing Remarks | Rakesh Jain |



